LOS ANGELES, May 9, 2003 -- Chances that a proposed drug for use against SARS will prove effective against the deadly pneumonia epidemic were sharply improved by findings that only insignificant mutations are occurring in the cornoavirus identified as its cause, according to a respected British medical journal, making it a stable target for rapidly-produced "antisense" drugs that prime the immune system to prepare it for the SARS virus and then attack it when the victim is infected. Corvallis, Ore.-based AVI BioPharma CEO Dennis Burger told Congress in sworn testimony May 7 that he believes a compound newly created by...
